We assessed whether other cancer driver gene alterations found in CRC, such as those in TP53, SMAD4, PIK3CA, KRAS, ARID1A, SOX9 and FAM123B correlated with sensitivity to MSC2504877, but did not find, in this tumour cell line panel at least, that gene mutations/copy number alterations in any of these strongly correlated with tankyrase inhibitor response. This evidence concerns the gene AMER1 and colorectal carcinoma.